High Risk Pregnant Women Undergoing Elective Cesarean Section
Conditions
Keywords
high risk pregnancy, cesarean section., tranexamic acid
Brief summary
The aim of the study is to assess the prophylactic role of tranexamic acid in reducing blood loss during and after elective cesarean section delivery in high risk patients. Comparing effect of administration of 1gm of TXA half an hour before elective C-section , effect of administration of 1gm of TXA on the start of uterine incision and placebo effect, Where in all an addition of prophylactic uterotonics is given, in a randomized control, double blind trial of 3 groups.
Detailed description
All patients will undergo the following I. History : Medical history, Obstetric history, Comorbidities, Allergies. II. Clinically: Vital signs, Abdomino-pelvic examination, per-vaginal examination. III. Laboratory: Hemoglobin, Hematocrit before & after cesarean section. IV. Routine Ultrasound. V. Cesarean section: done under spinal anathesia. VI. Calculation of blood loss: The quantity of blood loss (ml) is calculated from 3 components : * (weight of used towels during surgery - weight of used towels prior to surgery),plus * (volume of blood sucked in suction container after placental delivery) ,plus * (weight of used vaginal pad in the first 2 hours after CS - the pad' s dry weight) * Each 1 mg increase the weight of either the towels or the vaginal pads is equivalent to 1 ml blood loss (Vitello, Dominic J., et al). VII. Informed Consent: will be obtained from all participants including the pregnant women who are included in the study . All patients will receive routine ecbolics ( oxytocin ) after delivery of baby.
Interventions
IV 1gm
Sponsors
Study design
Eligibility
Inclusion criteria
* High risk women undergoing elective C-section * Hypertensive patients. * Obese patients. * Patients on LMWH. * Transverse lie * DM ( Type 1 & Gestational ) * Cardiac ( Not on Anticoagulants ) * Placenta Previa ( Not in PAS ) * Previous uterine scar ( \> previous 2 C- section )
Exclusion criteria
* Patients with bleeding tendency. * HELLP Syndrome. * Emergency C- section. * Mechanical prosthetic valve * Atrial Fibrillation. * Allery to tranexamic acid * Placenta Accreta , Increta , percreata.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of blood loss during C-section. | 1 hour | ml |
| Prevention of 1ry postpartum hemorrhage. | 24 hours | ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of hospital stay. | 48 hours | Number of days |
| Decrease risk of maternal blood transfusion | 48 hours | Number of blood products units |
Countries
Egypt